Additionally, ADA guidelines recommend prescribing angiotensin-converting-enzyme inhibitors (ACEi) or angiotensin 2 receptor blockers (ARBs) and high-intensity statins (defined as atorvastatin 40–80 mg daily or rosuvastatin 20–40 mg daily) for ASCVD patients to confer additional cardiovascular protection (Association, 2021, 2022; ElSayed et al., 2023; “Standards of Medical Care in Diabetes-2020 Abridged for Primary Care Providers”, 2020). The gene discussed is ACE; the disease is diabetes mellitus.